Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

United Therapeutics Chairperson & CEO Martine Rothblatt exercised stock options and sold 8,000 common shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported transactions involving the company's common stock.
• On November 12, 2025, Rothblatt exercised 4,000 stock options at an exercise price of $120.26 per share.
• Immediately following the option exercise on November 12, 2025, Rothblatt sold a total of 4,000 common shares in multiple transactions at weighted average prices ranging from $455.97 to $463.235.
• On November 13, 2025, Rothblatt exercised an additional 4,000 stock options at an exercise price of $120.26 per share.
• Following the option exercise on November 13, 2025, Rothblatt sold a total of 4,000 common shares in multiple transactions at weighted average prices ranging from $458.475 to $467.3858.
• All exercises and sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on May 2, 2025.
• The 10b5-1 plan is set to continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire March 15, 2026, or December 31, 2025.
• After these transactions, Rothblatt directly owns 130 common shares and indirectly owns 386,393 common shares through a spouse and various family trusts.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions under a pre-arranged 10b5-1 plan. This type of filing is generally neutral in sentiment as it reflects executive compensation management rather than new operational or financial news.

Positives

• The transactions were executed at significantly higher prices ($455.97 $467.3858) compared to the option exercise price ($120.26), indicating substantial gains for the reporting person.
• The sales were conducted under a pre-arranged 10b5-1 trading plan, which demonstrates a systematic approach to managing equity holdings and reduces concerns about opportunistic insider selling.

Negatives

• No direct negative implications are apparent from this routine insider transaction report.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4 filing, which primarily reports executive stock transactions.

Future Outlook

This Form 4 filing, detailing executive stock transactions, does not provide specific forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• No direct quotes or paraphrased statements from company management are provided in this transactional filing.

Industry Context

The reported transactions are routine insider sales executed under a pre-arranged 10b5-1 plan, which is a common practice for executives to diversify holdings and manage equity compensation. These transactions do not inherently reflect specific industry trends or competitive positioning, but rather individual financial planning.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for executive stock sales is a standard corporate governance practice across industries, designed to mitigate concerns about insider trading based on material non-public information.
• The volume of shares sold (8,000 shares) represents a portion of the executive's overall equity compensation and beneficial ownership, which is typical for executives managing their portfolios over time.

Stakeholder Impact

• Shareholders: Routine insider sales under a 10b5-1 plan typically have minimal direct impact on shareholder confidence, as they are pre-scheduled and not indicative of new information.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The pre-arranged 10b5-1 trading plan will continue until the earlier of the exhaustion of a tranche of 294,000 stock options that expire March 15, 2026, or December 31, 2025.

Key Dates

Recommendation

The filing details routine insider stock option exercises and sales executed under a pre-arranged 10b5-1 trading plan. Such transactions are part of an executive's long-term financial planning and compensation management, rather than a reaction to new material information about the company's performance or outlook. Therefore, this filing alone does not provide a basis for changing an investment recommendation, and a 'hold' stance is appropriate as it does not signal new positive or negative catalysts.

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Executive Compensation, Share Sale